Argan (AGX) Cash & Equivalents (2010 - 2026)

Argan has reported Cash & Equivalents for 17 years, with the latest figure at $339.5 million in Q1 2026.

• Quarterly Cash & Equivalents rose 133.7% year-over-year to $339.5 million in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $339.5 million (up 133.7% YoY) and the FY2026 annual result came in at $339.5 million, up 133.7% from the prior year.
• Cash & Equivalents grew to $339.5 million in Q1 2026 per AGX's latest filing, from $306.3 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $350.5 million in Q1 2022 and troughed at $136.1 million in Q4 2022.
• A 5-year average of $209.0 million and a median of $192.3 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents tumbled 68.25% in 2022, then surged 133.7% in 2026.
• Over 5 years, Cash & Equivalents stood at $136.1 million in 2022, then jumped by 36.38% to $185.6 million in 2023, then declined by 5.51% to $175.3 million in 2024, then soared by 74.68% to $306.3 million in 2025, then increased by 10.84% to $339.5 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $339.5 million, $306.3 million, and $177.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.